MA46890A - Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme - Google Patents

Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme

Info

Publication number: MA46890A
Authority: MA; Morocco
Prior art keywords: complications; acute; improvement; reduction; long
Prior art date: 2016-11-28

Application number

MA046890A

Other languages

English (en)

Inventor

Per Knud Christensen

Thue Johansen

Kajsa Kvist

Simon Skibsted

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-28

Filing date

2017-11-28

Publication date

2021-04-28

2017-11-28 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2021-04-28 Publication of MA46890A publication Critical patent/MA46890A/fr

Links

FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 title 1
230000001154 acute effect Effects 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
230000002641 glycemic effect Effects 0.000 title 1
108010050259 insulin degludec Proteins 0.000 title 1
229960004225 insulin degludec Drugs 0.000 title 1
230000007774 longterm Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Immunology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA046890A 2016-11-28 2017-11-28 Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme MA46890A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16200993		2016-11-28
EP17162803		2017-03-24
EP17174687		2017-06-07

Publications (1)

Publication Number	Publication Date
MA46890A true MA46890A (fr)	2021-04-28

Family

ID=60702634

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA046890A MA46890A (fr)	2016-11-28	2017-11-28	Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme

Country Status (6)

Country	Link
US (1)	US11673933B2 (fr)
EP (1)	EP3544682A1 (fr)
JP (1)	JP2019535791A (fr)
CN (1)	CN110099719A (fr)
MA (1)	MA46890A (fr)
WO (1)	WO2018096163A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA46890A (fr)	2016-11-28	2021-04-28	Novo Nordisk As	Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
EP3544683A1 (fr)	2016-11-28	2019-10-02	Novo Nordisk A/S	Insuline dégludec utilisée dans des conditions cardiovasculaires
AR112015A1 (es)	2017-06-09	2019-09-11	Novo Nordisk As	Composiciones sólidas para administración oral
US20230158234A1 (en) *	2021-11-22	2023-05-25	Colleen Cook	Method of Insulin Administration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122009000079I2 (de)	1996-08-30	2011-06-16	Novo Nordisk As Novo Alle	Glp-1 derivate
GB0309154D0 (en)	2003-01-14	2003-05-28	Aventis Pharma Inc	Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
AU2004261353B2 (en)	2003-08-05	2009-12-10	Novo Nordisk A/S	Novel insulin derivatives
IN2014KN02335A (fr) *	2012-03-28	2015-05-01	Sanofi Sa
US20160296602A1 (en) *	2013-03-20	2016-10-13	Novo Nordisk A/S	Dosing Regimen
EP2991672A1 (fr) *	2013-04-30	2016-03-09	Novo Nordisk A/S	Schéma d'administration d'un nouveau type
MA46890A (fr)	2016-11-28	2021-04-28	Novo Nordisk As	Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme

2017
- 2017-11-28 MA MA046890A patent/MA46890A/fr unknown
- 2017-11-28 EP EP17816532.0A patent/EP3544682A1/fr not_active Withdrawn
- 2017-11-28 JP JP2019528540A patent/JP2019535791A/ja not_active Withdrawn
- 2017-11-28 US US16/463,594 patent/US11673933B2/en active Active
- 2017-11-28 WO PCT/EP2017/080603 patent/WO2018096163A1/fr not_active Ceased
- 2017-11-28 CN CN201780073532.XA patent/CN110099719A/zh not_active Withdrawn

Also Published As

Publication number	Publication date
EP3544682A1 (fr)	2019-10-02
CN110099719A (zh)	2019-08-06
US20200181222A1 (en)	2020-06-11
JP2019535791A (ja)	2019-12-12
WO2018096163A1 (fr)	2018-05-31
US11673933B2 (en)	2023-06-13

Similar Documents

Publication	Publication Date	Title
IL273620A (en)	2020-05-31	Recombinant collagen and elastin molecules and their uses
ZA202007868B (en)	2023-06-28	Anti-n3pglu amyloid beta peptide antibodies and uses thereof
EP3681563A4 (fr)	2021-09-15	Expérience utilisateur pour pompes à perfusion
EP3437495A4 (fr)	2019-12-11	Cartouche pour inhalateur d'arôme et inhalateur d'arôme
EP3392324A4 (fr)	2019-07-31	Composition de cristaux liquides et élément d'affichage à cristaux liquides
EP3323873A4 (fr)	2019-03-13	Composition de cristaux liquides et élément d'affichage à cristaux liquides
EP3392325A4 (fr)	2019-07-31	Composition de cristaux liquides et élément d'affichage à cristaux liquides
MX380322B (es)	2025-03-12	Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1).
EP3495016A4 (fr)	2019-10-23	Aiguille à soupape et ensemble d'aiguille à soupape à demeure
IL248508B (en)	2022-10-01	Compositions comprising aav expressing dual antibody constructs and uses thereof
EP3450523A4 (fr)	2020-01-01	Composition de cristaux liquides et élément d'affichage à cristaux liquides
EP3466918A4 (fr)	2020-01-08	Composé polaire polymérisable, composition de cristaux liquides, et élément d'affichage à cristaux liquides
IL240285A0 (en)	2015-09-24	Biomarkers for type ii diabetes and their uses
DK3280432T3 (da)	2021-04-26	Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
EP3018186A4 (fr)	2016-06-29	Composition à cristaux liquides et élément d'affichage à cristaux liquides
SI3247388T1 (sl)	2026-02-27	Rekombinantni humani/bovini virus parainfluence 3 (b/hpiv3) z izraženo himerno beljakovino rsv/bpiv3
BR112018067731A2 (pt)	2019-01-08	coagonistas de glucagon e glp-1 para o tratamento de obesidade
EP3425025A4 (fr)	2019-07-31	Composition de cristaux liquides et élément d'affichage à cristaux liquides
EP3302621A4 (fr)	2019-05-08	Programmation basée sur une procédure pour pompes à perfusion
GB2553706B (en)	2020-12-16	Electro-optic and thermo-optic modulator
IL268874A (en)	2019-10-31	Peptides and methods for the treatment of diabetes
PL3658115T3 (pl)	2022-08-08	Kompozycje w postaci wodnego roztworu do wstrzykiwań zawierające co najmniej insulinę ludzką a21g i co najmniej jeden supresor glukagonu o działaniu prandialnym
EP3600174C0 (fr)	2025-11-05	Cathéter de pose d'endoprothèse avec commande de curseur rapide et molette lente
EP2884334A4 (fr)	2016-06-29	Elément d'affichage à cristaux liquides
EP3969467A4 (fr)	2023-07-05	Analogues de l'insuline monocaténaire variante